NCT06409507View on ClinicalTrials.gov

Research and Application for New Clinical Diagnosis and Treatment System for HBV Related HCC Liver Transplantation

CompletedOBSERVATIONAL
Enrollment

178

Participants

Timeline

Start Date

January 1, 2015

Primary Completion Date

January 1, 2021

Study Completion Date

August 1, 2023

Conditions
Hepatocellular CarcinomaLiver TransplantationPrognosis
Interventions
GENETIC

FKBP12 expression

The expressions of FKBP12 were determined by immunohistochemistry (IHC) , and the immunoreactive score (IRS), calculated by multiplying the staining intensity grades by the proportion of positive cells, was used to assess the expression levels of FKBP12. IRS (0-7) represented low expression levels, and IRS (8-12) represented high expression levels.

All Listed Sponsors
lead

First People's Hospital of Hangzhou

OTHER

NCT06409507 - Research and Application for New Clinical Diagnosis and Treatment System for HBV Related HCC Liver Transplantation | Biotech Hunter | Biotech Hunter